UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Group approach may increase accessibility to psychedelic therapy
In a bid to increase accessibility, a new study by the Australian National University (ANU) School of Medicine and Psychology will look into the viability of the application of psychedelics in a group setting. The study will focus on the psychological, cognitive and physical effects, including adverse events, of taking psilocybin and MDMA in a group setting.
“We don’t want to run before we walk”: the attitudes of Australian stakeholders towards using psychedelics for mental health conditions
Additional research and a clear presentation of this research are needed before the clinical use of psychedelics can be supported.
Experts' mixed responses to the surprise announcement of psilocybin & MDMA becoming (limitedly) licensed in Australia
The Australian Therapeutic Goods Administration has announced that psilocybin for treatment-resistant depression and MDMA for PTSD will be legally prescribable.
Australia becomes first country to recognise psychedelics as medicines
In a surprising move, Australia’s Therapeutic Goods Administration (TGA) has announced that it will permit the prescribing of MDMA and Psilocybin from the 1st of July.